Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000413629 | SCV000492182 | uncertain significance | not provided | 2017-09-14 | criteria provided, single submitter | clinical testing | The R888Q variant in the C2CD3 gene has not been reported previously as a pathogenic variant, nor as a benign variant, to our knowledge. The R888Q variant is observed in 3/11558 (0.026%) alleles from individuals of Latino background and in 14/66664 (0.021%) alleles from individuals of non-Finnish European background in the ExAC dataset (Lek et al., 2016). The R888Q variant is a semi-conservative amino acid substitution, which may impact secondary protein structure as these residues differ in some properties. This substitution occurs at a position that is not conserved. In silico analysis is inconsistent in its predictions as to whether or not the variant is damaging to the protein structure/function. We interpret R888Q as a variant of uncertain significance. |
Labcorp Genetics |
RCV000413629 | SCV002149893 | likely benign | not provided | 2025-01-22 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004022176 | SCV004914530 | uncertain significance | Inborn genetic diseases | 2024-12-06 | criteria provided, single submitter | clinical testing | The c.2663G>A (p.R888Q) alteration is located in exon 15 (coding exon 15) of the C2CD3 gene. This alteration results from a G to A substitution at nucleotide position 2663, causing the arginine (R) at amino acid position 888 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Breakthrough Genomics, |
RCV000413629 | SCV005190461 | uncertain significance | not provided | criteria provided, single submitter | not provided |